'By no means are we deterred': Seres' stock spirals after PhII microbiome fail in ulcerative colitis

Nicole DeFeudis

Editor

Almost five years after Seres Therapeutics slammed into a Phase II failure with its lead candidate, the microbiome pioneer is reporting another massive flop …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'By no means are we deterred': Seres' stock spirals after PhII microbiome fail in ulcerative colitis

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

How AI can address ongoing challenges in the life sciences industry

'By no means are we de­terred': Seres' stock spi­rals af­ter PhII mi­cro­bio­me fail in ul­cer­a­tive col­i­tis

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'By no means are we deterred': Seres' stock spirals after PhII microbiome fail in ulcerative colitis